Vertex’s Suzetrigine Disappoints In Phase II Pain Study, But Phase III Planning Under Way

Acute Pain Approval Decision Due 30 January

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.